Synonym
Revexepride monohydrochloride monohydrate; Revexepride HCl; Revexepride hydrate; Revexepride hydrochloride
IUPAC/Chemical Name
4-amino-5-chloro-N-(((3S,4S)-3-hydroxy-1-(3-methoxypropyl)piperidin-4-yl)methyl)-2,2-dimethyl-2,3-dihydrobenzofuran-7-carboxamide hydrochloride hydrate
InChi Key
PBUJIMKARWFIMP-YUANJJMISA-N
InChi Code
InChI=1S/C21H32ClN3O4.ClH.H2O/c1-21(2)10-15-18(23)16(22)9-14(19(15)29-21)20(27)24-11-13-5-7-25(12-17(13)26)6-4-8-28-3;;/h9,13,17,26H,4-8,10-12,23H2,1-3H3,(H,24,27);1H;1H2/t13-,17+;;/m0../s1
SMILES Code
O.Cl.COCCCN1CC[C@@H](CNC(=O)C2=CC(Cl)=C(N)C3=C2OC(C)(C)C3)[C@H](O)C1
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
480.43
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Pierce D, Corcoran M, Velinova M, Hossack S, Hoppenbrouwers M, Martin P. A
phase 1 randomized study evaluating the effect of omeprazole on the
pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride
(SSP-002358), in healthy adults. Drug Des Devel Ther. 2015 Feb 27;9:1257-68. doi:
10.2147/DDDT.S64621. eCollection 2015. PubMed PMID: 25767373; PubMed Central
PMCID: PMC4354395.
2: Shaheen NJ, Adler J, Dedrie S, Johnson D, Malfertheiner P, Miner P, Meulemans
A, Poole L, Tack J, Thielemans L, Troy S, Vakil N, Zerbib F, Ruth M. Randomised
clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal
reflux disease who have persistent symptoms despite PPI therapy. Aliment
Pharmacol Ther. 2015 Apr;41(7):649-61. doi: 10.1111/apt.13115. Epub 2015 Feb 19.
PubMed PMID: 25693609.
3: Tack J, Zerbib F, Blondeau K, des Varannes SB, Piessevaux H, Borovicka J, Mion
F, Fox M, Bredenoord AJ, Louis H, Dedrie S, Hoppenbrouwers M, Meulemans A, Rykx
A, Thielemans L, Ruth M. Randomized clinical trial: effect of the 5-HT4 receptor
agonist revexepride on reflux parameters in patients with persistent reflux
symptoms despite PPI treatment. Neurogastroenterol Motil. 2015 Feb;27(2):258-68.
doi: 10.1111/nmo.12484. Epub 2014 Dec 21. PubMed PMID: 25530111; PubMed Central
PMCID: PMC4681320.
